-
Algernon Pharmaceuticals Provides Year End Summary of Key Activities
… & Women’s Hospital, Human Research Ethics Committee. July 7 … efficiently and safely into new human trials, developing new formulations … the U.S. or Europe to avoid off label prescription … has filed new intellectual property rights globally for NP-120 ( …
-
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
… Committee for Medicinal Products for Human Use (CHMP). Marek Kania, … Chi-Med currently retains all rights to surufatinib worldwide. About … to the EMA in Europe. The basis to support … 7340 (Mobile) bmiles@troutgroup.com Europe – Ben Atwell / Alex …
-
Canon Europe, the Middle East and Africa (EMEA) expands Ambassador Programme to over 100 leading international photographers and filmmakers including risings stars of the future
… their health, sexuality, education and human rights. Having worked extensively across Africa … (CME), a subsidiary of Canon Europe. The formation of CCNA in …
-
Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta
… to approval; Mereo retains commercial rights in Europe, Ultragenyx commercializes in US … an investigational anti-sclerostin fully human monoclonal antibody that has shown … treatments. Setrusumab is a fully human monoclonal antibody that inhibits sclerostin …
-
Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta
… to approval; Mereo retains commercial rights in Europe, Ultragenyx commercializes in US … an investigational anti-sclerostin fully human monoclonal antibody that has shown … treatments. Setrusumab is a fully human monoclonal antibody that inhibits sclerostin …
-
Human rights breaches in China and Iran | News | European Parliament
On Thursday, the European Parliament adopted two resolutions taking stock of the human rights situation in China and Iran.Committee on Foreign AffairsSubcommittee on Human Rights Source : © European Union, 2020 – EP
-
Algernon Pharmaceuticals Provides Additional Information on Phase 2b/3 Ifenprodil COVID-19 Study Interim Data
… efficiently and safely into new human trials, developing new formulations and … in the U.S. or Europe to avoid off label prescription … has filed new intellectual property rights globally for NP-120 (Ifenprodil …
-
Algernon CEO and CSO to Discuss COVID-19 Interim Data Results Featured on BioPub Webcast Hosted by Dr. KSS MD PhD
… efficiently and safely into new human trials, developing new formulations and … in the U.S. or Europe to avoid off label prescription … has filed new intellectual property rights globally for NP-120 (Ifenprodil …
-
First-in-class cholesterol-lowering treatment NILEMDO® * (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® * (bempedoic acid and ezetimibe) tablet approved in Switzerland
… Sankyo has licensed exclusive commercialization rights to bempedoic acid and the … ® (bempedoic acid) Product Information for Human Medicinal Products. December 2020. (10 … Contacts: Daiichi Sankyo Europe GmbH Dr. Wolfgang Schiessl (Europe) Director Product PR …
-
AB Science announces that Phase 2B/3 study evaluating oral in Alzheimer’s disease met its primary endpoint
… AB Science to retain exclusive rights on the use of masitinib … 2020. US: 11am-12am EST; Europe 5pm-6pm CET. Webcast Dial … disease), consultant for the Human Frontier Program and Expert of … medicine and is developed in human medicine in oncology, neurological …